1-(3-methoxypropyl)indazole-3-carbaldehyde | 897948-42-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1-(3-methoxypropyl)indazole-3-carbaldehyde
• 英文别名: 1-(3-methoxypropyl)-1H-indazol-3-carbaldehyde
• CAS: 897948-42-4
• 化学式: C₁₂H₁₄N₂O₂
• 分子量: 218.255
• InChiKey: YTDWIOGRQJUQIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3-methoxypropyl)indazole-3-carbaldehyde 在 sodium tetrahydroborate 、 乙醇 作用下， 以 乙醇 为溶剂， 反应 2.5h， 生成 N-{[1-(3-methoxypropyl)indazol-3-yl]methyl}cyclopropanamine
  参考文献：
  名称：

  SPH3127的发现：一种新型的、高效的、具有口服活性的直接肾素抑制剂

  摘要：

  肾素是肾素-血管紧张素-醛固酮系统 (RAAS) 中的限速酶，可调节血压和肾功能，因此是治疗高血压和心血管/肾脏疾病的有吸引力的靶标。然而，多年来，开发具有良好口服生物利用度的直接肾素抑制剂 (DRI) 一直是一项长期挑战。这个问题被认为是因为大多数报道的 DRI 是肽样结构或非肽样结构，分子量 (MW) > 600。因此，我们试图找到 MW < 500 的非肽模拟 DRI，并发现有前景的2-氨基甲酰基吗啉衍生物4．在我们努力改善4在没有显着增加 MW 的情况下，我们发现了化合物18 (SPH3127)，它在临床前模型中表现出比阿利吉仑更高的生物利用度和更有效的抗高血压作用，并已完成原发性高血压的 II 期临床试验。

  DOI：

  10.1021/acs.jmedchem.2c00834
• 作为产物：
  描述：

  [1-(3-methoxypropyl)-1H-indazol-3-yl]methanol 在 manganese(IV) oxide 作用下， 以 甲苯 为溶剂， 反应 12.0h， 生成 1-(3-methoxypropyl)indazole-3-carbaldehyde
  参考文献：
  名称：

  WO2006/69788

  摘要：

  公开号：

文献信息

• 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES
  申请人：Masuya Keiichi

  公开号：US20100029647A1

  公开（公告）日：2010-02-04

  3,4(,5)-substituted tetrahydropyridine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4(,5)-substituted tetrahydropyridine compound, and/or a method of treatment comprising administering a 3,4(,5)-substituted tetrahydropyridine compound, a method for the manufacture of a 3,4(,5)-substituted tetrahydropyridine compound, and novel intermediates and partial steps for its synthesis. The 3,4(,5)-substituted tetrahydropyridine compounds have the formula I wherein the substituents and symbols are as described in the specification.

  3,4(,5)-取代四氢吡啶化合物，这些化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病；该类化合物用于制备治疗依赖于肾素活性疾病的制药配方；该类化合物用于治疗依赖于肾素活性的疾病；包含3,4(,5)-取代四氢吡啶化合物的制药配方，和/或包括给予3,4(,5)-取代四氢吡啶化合物的治疗方法，以及制备3,4(,5)-取代四氢吡啶化合物的方法，以及其合成的新中间体和部分步骤。3,4(,5)-取代四氢吡啶化合物的化学式为I，其中取代基和符号如说明书所述。
• MORPHOLINE DERIVATIVE
  申请人：Akatsuka Hidenori

  公开号：US20100240644A1

  公开（公告）日：2010-09-23

  The present invention provides a morpholine derivative of the formula [I]; wherein R 1 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, a cycloalkyl group or an alkyl group; R 2 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, an optionally substituted alkylcarbonyl group, an optionally substituted arylcarbonyl group, an optionally substituted heterocyclo-substituted carbonyl group or a cycloalkylcarbonyl group; T is a methylene group or a carbonyl group; R 3 , R 4 , R 5 and R 6 are the same or different and a hydrogen atom, an optionally substituted carbamoyl group or an optionally substituted alkyl group; or pharmaceutically acceptable salts thereof. These compounds are useful as a renin inhibitor.

  本发明提供了公式[I]的吗啡啶衍生物；其中R1是取代的烷基，可选取代的芳基，可选取代的杂环基，环烷基或烷基；R2是取代的烷基，可选取代的芳基，可选取代的杂环基，可选取代的烷基羰基，可选取代的芳基羰基，可选取代的杂环取代羰基或环烷基羰基；T是亚甲基或羰基；R3，R4，R5和R6相同或不同，是氢原子，可选取代的氨基甲酰基或可选取代的烷基；或其药学上可接受的盐。这些化合物可用作肾素抑制剂。
• AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS
  申请人：Cadieux Jean-Jacques

  公开号：US20100240713A1

  公开（公告）日：2010-09-23

  This invention is directed to compounds of formula (I), wherein m, formula (II), R 1 , R 2 and R 3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

  本发明涉及式（I）的化合物，其中m、式（II）、R1、R2和R3如本文所定义，作为立体异构体、对映异构体、互变异构体或其混合物；或其药学上可接受的盐、溶剂或前药，用于治疗铁代谢紊乱。本发明还涉及包含该化合物的制药组合物以及使用该化合物治疗铁代谢紊乱的方法。
• Organic compounds
  申请人：Novartis AG

  公开号：EP2177518A1

  公开（公告）日：2010-04-21

  3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4-substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula I, wherein the symbols have the meanings defined in the specification.

  3,4-取代的哌啶化合物，这些化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病（=失调）；该类化合物用于制备治疗依赖于肾素活性的疾病的药物制剂；公开了该类化合物在治疗依赖肾素活性的疾病中的用途；包含3,4-取代的哌啶化合物的药物制剂，和/或包括施用3,4-取代的哌啶化合物的治疗方法，3,4-取代的哌啶化合物的制造方法，以及新型中间体及其合成的部分步骤。3,4-二取代哌啶化合物具有式 I、 其中符号具有本说明书中定义的含义。
• ORGANIC COMPOUNDS
  申请人：Breitenstein Werner

  公开号：US20090312304A1

  公开（公告）日：2009-12-17

  3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4-substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula I,